ARTICLE HERO IMAGE
Summary

Asbestos mass tort litigation reshaped the insurance industry for decades. This analysis compares the characteristics of asbestos and PFAS claims and finds that, unless something significant changes the current path of PFAS litigation and regulation, PFAS could become a toxic tort of similar scale to asbestos liability, or even greater. Organizations should proactively prepare for the level of claims handling that appears to be coming.

What made asbestos the defining mass tort

Asbestos remains the longest-running and most costly mass tort in American history. Widespread industrial use, latent disease that surfaces decades after exposure, and a broad universe of potentially responsible parties combined to produce waves of claims that reshaped the insurance industry and drove a generation of defendants into bankruptcy.

Those same features are the reason asbestos is the natural benchmark when a new contaminant begins to move through the courts. Understanding why asbestos behaved the way it did is the starting point for judging what may come next.

Why PFAS looks familiar

Per- and polyfluoroalkyl substances share several of the traits that made asbestos so difficult to contain. PFAS were used across a wide range of products and industries, they are persistent and mobile in the environment, and the science linking exposure to health effects continues to develop. Together, these characteristics create the conditions for a large and durable pool of claims.

EXHIBIT: ASBESTOS VS. PFAS COMPARISON

The scale of potential litigation

This comparison suggests that, unless something significant changes the current path of PFAS litigation and regulation, PFAS could be a toxic tort of similar scale to asbestos liability, or even greater. The breadth of potentially responsible parties and the volume of impacted sites point toward claim activity that could extend well into the future.

What it means for insurers

For the insurance industry, the parallel matters most in how exposure accumulates over time. Long-tail claims, evolving coverage questions, and uncertainty around allocation all echo the asbestos experience. Insurers and their policyholders face the prospect of a daunting level of claims handling if the trajectory holds.

How to prepare now

Organizations dealing with PFAS should proactively prepare for the expectation of a significant volume of claims rather than wait for the litigation to arrive. Early assessment of exposure, disciplined data management, and coordinated technical and economic analysis are the most reliable ways to avoid getting caught in the PFAS litigation avalanche that appears to be coming.

Frequently Asked Questions

The two share the traits that made asbestos so costly: widespread use, persistence, latent health effects, and a broad universe of potentially responsible parties. That combination is what makes asbestos the natural benchmark for judging how PFAS litigation may unfold.
The analysis concludes that, unless something significant changes the current path of PFAS litigation and regulation, PFAS could be a toxic tort of similar scale to asbestos liability, or even greater.
Roux supports PFAS matters with site investigation, exposure and risk assessment, claims data management, and the economic and technical analysis behind allocation and litigation. One firm, one senior team.